ArticleFrontiers in pharmacology2022
Atractylenolide III Attenuates Angiogenesis in Gastric Precancerous Lesions Through the Downregulation of Delta-Like Ligand 4.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- A systematic review on the application, phytochemistry and pharmacological activities of the genus Atractylodes.Chinese medicine · 2026Review
- Anticancer Potential of Atractylenolides I-III: Efficacy, Mechanisms, Pharmacokinetics, and Safety.Molecules (Basel, Switzerland) · 2026Review
- Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026Review
- Gastrointestinal microbiota in treatment of gastric precancerous lesions and gastric cancer by Western and traditional Chinese medicine.World journal of clinical oncology · 2025Review
- Natural products based on Correa's cascade for the treatment of gastric cancer trilogy: Current status and future perspective.Journal of pharmaceutical analysis · 2025Review
- Research progress on the therapeutic effects of effective components of traditional Chinese medicine in the treatment of gastric cancer precursors through modulation of multiple signaling pathways.Frontiers in oncology · 2025Review
- Advances in modeling gastric intestinal metaplasia: a comprehensive review of experimental models and mechanistic insights.Frontiers in oncology · 2025Review
- Article
- Longitudinal gut fungal alterations and potential fungal biomarkers for the progression of primary liver disease.Science China. Life sciences · 2024Article
- Current study of pathogenetic mechanisms and therapeutics of chronic atrophic gastritis: a comprehensive review.Frontiers in cell and developmental biology · 2024Review
- Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer.Frontiers in oncology · 2024Review
- Chemical Constitution, Pharmacological Effects and the Underlying Mechanism of Atractylenolides: A Review.Molecules (Basel, Switzerland) · 2023Review
- Traditional Chinese medicine for transformation of gastric precancerous lesions to gastric cancer: A critical review.World journal of gastrointestinal oncology · 2023Review
- The effect of phytochemicals in N-methyl-N-nitro-N-nitroguanidine promoting the occurrence and development of gastric cancer.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.